公开(公告)号：US20180162875A1

公开(公告)日：2018-06-14

申请号：US15845621

申请日：2017-12-18

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20220098180A1

公开(公告)日：2022-03-31

申请号：US17426971

申请日：2020-01-29

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro ITO ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Hideyuki SUGIYAMA ,  Tohru MIYAZAKI ,  Yasuyoshi ARIKAWA ,  Tomohiro OKAWA ,  Jinichi YONEMORI ,  Osamu KUBO ,  Akinori TOITA ,  Takuto KOJIMA ,  Fumiaki KIKUCHI ,  Minoru SASAKI ,  Misaki HOMMA ,  Yasuhiro IMAEDA ,  Hironobu MAEZAKI ,  Shiinobu SASAKI ,  Ayumu SATO ,  Hirotaka KAMITANI ,  Yasutomi ASANO ,  Hironori KOKUBO ,  Masato YOSHIKAWA

IPC: C07D413/10 ,  C07D271/06 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20210139491A1

公开(公告)日：2021-05-13

申请号：US16622632

申请日：2018-06-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kazuaki TAKAMI ,  Masaki SETO ,  Shinobu SASAKI ,  Haruhi ANDO ,  Masaki OGINO ,  Tomoko OHASHI ,  Toshihiro IMAEDA ,  Ikuo FUJIMORI ,  Yasuhiro TSUKIMI ,  Masami YAMADA ,  Kenichiro SHIMOKAWA ,  Takeshi WAKABAYASHI ,  Masataka MURAKAMI ,  Makoto FUSHIMI ,  Tomohiro OKAWA ,  Jinichi YONEMORI ,  Tomohiro OHASHI ,  Hideo SUZUKI ,  Hironobu MAEZAKI ,  Ayumu SATO ,  Yasutomi ASANO ,  Steve SWANN

IPC: C07D491/048 ,  A61K31/4355 ,  A61P1/10

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20190169166A1

公开(公告)日：2019-06-06

申请号：US16323863

申请日：2017-08-09

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Jun FUJIMOTO ,  Xin LIU ,  Osamu KURASAWA ,  Terufumi TAKAGI ,  Douglas Robert CARY ,  Hiroshi BANNO ,  Yasutomi ASANO ,  Takuto KOJIMA

IPC: C07D401/12 ,  C07D239/42 ,  A61P35/00

Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20150353578A1

公开(公告)日：2015-12-10

申请号：US14804935

申请日：2015-07-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Abstract translation: 提供由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐，其具有AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体 增效作用 本发明的化合物可用作抑郁症，精神分裂症，阿尔茨海默病或注意缺陷多动障碍（ADHD）等的预防或治疗药物。

公开(公告)号：US20140080817A1

公开(公告)日：2014-03-20

申请号：US13774707

申请日：2013-02-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Abstract translation: 提供由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐，其具有AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体 增效作用 本发明的化合物可用作抑郁症，精神分裂症，阿尔茨海默病或注意缺陷多动障碍（ADHD）等的预防或治疗药物。

公开(公告)号：US20130184266A1

公开(公告)日：2013-07-18

申请号：US13774635

申请日：2013-02-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.